Premium
D‐Psicose, a Sweet Monosaccharide, Ameliorate Hyperglycemia, and Dyslipidemia in C57BL/6J db/db Mice
Author(s) -
Baek S.H.,
Park S.J.,
Lee H.G.
Publication year - 2010
Publication title -
journal of food science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 150
eISSN - 1750-3841
pISSN - 0022-1147
DOI - 10.1111/j.1750-3841.2009.01434.x
Subject(s) - medicine , endocrinology , dyslipidemia , glycemic , triglyceride , diabetes mellitus , monosaccharide , fructose , chemistry , type 2 diabetes , cholesterol , area under the curve , insulin , lipid profile , biochemistry
D‐psicose has been implicated in glycemic control in recent animal and human studies. In this study, the effects of D‐psicose on glycemic responses, insulin release, and lipid profiles were compared with those of D‐glucose and D‐fructose in a genetic diabetes model. C57BL/6J db/db mice were orally supplemented with 200 mg/kg BW of D‐psicose, D‐glucose, or D‐fructose, respectively, while diabetes control or wild type mice were supplemented with water instead. D‐psicose sustained weight gain by about 10% compared to other groups. The initial blood glucose level maintained from 276 to 305 mg/dL during 28 d in the D‐psicose group, whereas a 2‐fold increase was found in other groups ( P < 0.05) among diabetic mice. D‐psicose significantly improved glucose tolerance and the areas under the curve (AUC) for glucose among diabetes ( P < 0.05), but had no effect on serum insulin concentration. The plasma lipid profile was not changed by supplemental monosacchrides, although the ratio of LDL‐cholesterol/HDL‐cholesterol was ameliorated by D‐psicose. The administration of D‐psicose reversed hepatic concentrations of triglyceride (TG) and total cholesterol (TC) by 37.88% and 62.89%, respectively, compared to the diabetes control ( P < 0.05). The current findings suggest that D‐psicose shows promise as an antidiabetic and may have antidyslipidemic effects in type 2 diabetes.